Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure Quiz

John is a 59-year-old male with relapsed diffuse large B-cell lymphoma (DLBCL) who previously received CD19-targeted CAR T-cell therapy using a 4-1BB costimulatory domain but experienced disease progression within 6 months. He has no significant comorbidities and is currently on supportive care. He is now being evaluated for salvage therapy options including the novel huCART19-IL18 CAR T-cell therapy.

Question: Based on the phase 1 trial findings, what is the most appropriate counseling point regarding the expected efficacy and safety profile of huCART19-IL18 therapy for John?

Maria is a 65-year-old female with refractory B-cell lymphoma scheduled to receive huCART19-IL18 therapy after prior CD28-based CAR T failure. She has a history of mild baseline cytopenias and is concerned about potential side effects. Her current medications include prophylactic antibiotics and supportive care agents.

Question: What specific toxicity monitoring should the pharmacist emphasize for Maria during and after huCART19-IL18 infusion based on current evidence?

David is a 62-year-old male with relapsed/refractory B-cell lymphoma who failed initial CD19 CAR T-cell therapy with a CD28 costimulatory domain. He is considering options including a second standard CD19 CAR T infusion, an IL-18 armored CAR T-cell therapy, or alternative experimental CAR constructs. He has adequate organ function and no contraindications.

Question: Considering current evidence, which statement best guides the pharmacist’s recommendation regarding salvage CAR T-cell therapy options for David?